AstraZeneca Investor Day Presentation Deck
TOPAZ-1 has the potential to become the first-ever IO therapy
available for first-line, advanced biliary tract cancer patients
Lack of innovation in biliary tract cancer
10+ years
without innovation on top of standard of care
5% to 15%
of all patients with BTC surviving only five years¹
75%
of BTC patients present with advanced, unresectable BTC²
~50,000 people in the US, Europe
and Japan and about 210,000 people worldwide
are diagnosed with BTC each year³
TOPAZ-1 has practice-changing potential
• Trial stopped early at an interim analysis due to
clear efficacy, with almost
1 in 4
patients alive at two years
versus one in 10 on
chemotherapy alone
●
• Potential new standard of care in this
historically underserved cancer
Regulatory
submissions
in H1 2022
• Safety: no AE-related increase in discontinuations
First 10 therapy to demonstrate
long-term survival in first-line advanced BTC
27 1. Turkes F, et al. Gastroenterol Res Pract. 2019; 2019:7698786. 2. Vienot A and Neuzillet C. Clin Res Hepatol Gastroenterol. 2020;44:810-824 3. Siegel R, et al. CA Cancer J Clin. 2020; 70: 7-30. and Nakachi K, et al. Japanese Journal of
Clinical Oncology. 2018; 48(4): 392-395. and 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. AE = adverse events.View entire presentation